Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | PDE1B | Q01064 | 10/20 | 0.44 |
| ▸ | PDE1C | Q14123 | 10/20 | 0.44 |
| ▸ | PDE1A | P54750 | 9/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.42 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 4/20 | 0.34 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17674881 | 0.99 | ADORA3 (0.50) | ADORA3PDE1BPDE1CPDE1AHSD11B1 | |
| SCHEMBL19458530 | 0.92 | ADORA3 (0.49) | ADORA3PDE1BPDE1CPDE1AHSD11B1 | |
| SCHEMBL18185696 | 0.76 | PDE1B (0.54) | PDE1BPDE1CPDE1A | |
| SCHEMBL19458491 | 0.75 | PDE1B (0.50) | PDE1BPDE1CPDE1AHSD11B1MAPK13 | |
| SCHEMBL17674927 | 0.75 | PDE1B (0.53) | PDE1BPDE1CPDE1AHSD11B1DAO | |
| SCHEMBL21356663 | 0.74 | PDE1B (0.41) | PDE1BPDE1CPDE1ADAOBRD4 | |
| SCHEMBL19458490 | 0.72 | PDE1B (0.41) | PDE1BPDE1CPDE1AHSD11B1DAO | |
| SCHEMBL17675029 | 0.69 | PDE1C (0.65) | PDE1BPDE1CPDE1AHSD11B1BRD4 | |
| SCHEMBL17674992 | 0.69 | PDE1C (0.66) | PDE1BPDE1CPDE1AHSD11B1 | |
| SCHEMBL17674981 | 0.69 | PDE1C (0.66) | PDE1BPDE1CPDE1AHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3204387-B1 | TRIAZOLOPYRAZINONES AS PDE1 INHIBITORS | H LUNDBECK AS (DK) | 2019-06-12 | — | — | EP | disclosed |
| US-10150771-B2 | Triazolopyrazinones as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2018-12-11 | — | — | US | disclosed |
| US-20170298072-A1 | Triazolopyrazinones as PDE1 Inhibitors | H. LUNDBECK A/S (DK) | 2017-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10150771-B2 | Triazolopyrazinones as PDE1 inhibitors | PDE5A, PDE4A, PDE12 | ADORA3 1325/4885PDE1B 12/4885PDE1C 15/4885 |
| US-20170298072-A1 | Triazolopyrazinones as PDE1 Inhibitors | PDE5A, PDE4A, PDE12 | ADORA3 1325/4885PDE1B 12/4885PDE1C 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.